Long-term outcomes of pediatric-onset primary sclerosing cholangitis: A single-center experience in Japan.
autoimmune hepatitis
autoimmune sclerosing cholangitis
inflammatory bowel disease
liver transplantation
overlap syndrome
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
15
03
2019
revised:
27
07
2019
accepted:
05
08
2019
pubmed:
14
8
2019
medline:
14
8
2019
entrez:
14
8
2019
Statut:
ppublish
Résumé
Primary sclerosing cholangitis (PSC) is very rare in Japan. Although a large-scale cohort study of 781 pediatric-onset PSC patients in Europe and North America showed that the 5-year survival with native liver was 88%, the long-term outcomes of pediatric-onset PSC in Japan are unknown. Here, we evaluated the clinical outcomes of pediatric-onset PSC in Japan. We carried out a retrospective cohort study with a medical records review of pediatric PSC patients diagnosed between 1986 and 2017 at a single center. The PSC diagnoses were based on cholangiography, liver histology, and biochemical findings. The patients' survival was analyzed using the Kaplan-Meier method. Prognostic factors were determined by univariate and multivariate analyses using the Cox proportional hazards regression model. We identified 39 pediatric-onset PSC patients (22 boys, 17 girls). The median age at diagnosis was 9 years (interquartile range 6.0-13.5 years). The median follow-up period was 5.5 years (interquartile range 3.4-8.7 years). The phenotypes of PSC-autoimmune hepatitis, PSC-inflammatory bowel disease, and small-duct PSC were diagnosed in 13 (33.3%), 36 out of 38 (94.8%), and three (7.7%) patients, respectively. The 5-year liver transplantation-free survival of the whole cohort was 93.5%. Nine patients underwent liver transplantation, and four of these nine cases resulted in death. Both the univariate and multivariate analyses showed that the phenotype of "PSC-autoimmune hepatitis overlap" was an independent poor prognostic factor. The overall survival of pediatric-onset PSC in Japan was comparable to those in Western countries. The phenotype of PSC-autoimmune hepatitis was identified as a prognostic factor associated with a poorer long-term outcome.
Types de publication
Journal Article
Langues
eng
Pagination
1386-1397Informations de copyright
© 2019 The Japan Society of Hepatology.
Références
Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013; 382: 1587-1599.
Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678.
Lindor KD, Kowdley KV, Harrison ME. American College of G. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol 2015; 110: 646-659.
Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: Epidemiology and natural history. Hepatology 2013; 58: 1392-1400.
Weismuller TJ, Trivedi PJ, Bergquist A et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017; 152: 1975-1984.
Loftus EV Jr, Harewood GC, Loftus CG et al. PSC-IBD: A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96.
Nakazawa T, Naitoh I, Hayashi K et al. Inflammatory bowel disease of primary sclerosing cholangitis: A distinct entity? World J Gastroenterol 2014; 28(20): 3245-3254.
Jorgensen KK, Grzyb K, Lundin KE et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012; 18: 536-545.
Fevery J, Van Steenbergen W, Van Pelt J et al. Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD. Aliment Pharmacol Ther 2016; 43: 612-620.
Ricciuto A, Fish J, Carman N et al. Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2018; 16: 1098-1105.
Gregorio GV, Portmann B, Karani J et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology 2001; 33: 544-553.
Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: A long-term follow-up study. Hepatology 2003; 38: 210-217.
Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009; 7: 239-245.
Tenca A, Farkkila M, Arola J, Jaakkola T, Penagini R, Kolho KL. Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. United European Gastroenterol J 2016; 4: 562-569.
Rodrigues AT, Liu PM, Fagundes ED et al. Clinical characteristics and prognosis in children and adolescents with autoimmune hepatitis and overlap syndrome. J Pediatr Gastroenterol Nutr 2016; 63: 76-81.
Valentino PL, Wiggins S, Harney S, Raza R, Lee CK, Jonas MM. The natural history of primary sclerosing cholangitis in children: A large single-center longitudinal cohort study. J Pediatr Gastroenterol Nutr 2016; 63: 603-609.
Deneau MR, El-Matary W, Valentino PL et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology 2017; 66: 518-527.
Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol 2013; 59: 571-582.
Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review. J Hepatol 2012; 56: 1181-1188.
Lee WS, Lum SH, Lim CB et al. Characteristics and outcome of autoimmune liver disease in Asian children. Hepatol Int 2015; 9: 292-302.
Yoon J, Oh SH, Kim HJ et al. Primary sclerosing cholangitis with inflammatory bowel disease in Korean children. Pediatr Gastroenterol Hepatol Nutr 2015; 18: 268-275.
Umetsu S, Inui A, Sogo T, Komatsu H, Fujisawa T. Usefulness of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in children with primary sclerosing cholangitis. Hepatol Res 2018; 48: 355-363.
Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K, Takikawa H. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci 2014; 21: 43-50.
Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan--Analysis of 192 cases. J Gastroenterol 1997; 32: 134-137.
Takikawa H, Takamori Y, Tanaka A, Kurihara H, Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004; 29: 153-159.
Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013; 145: 521-536.
Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: A population-based analysis. Am J Gastroenterol 2007; 102: 1042-1049.
Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013; 58: 326-343.
Czaja AJ, Carpenter HA. Autoimmune hepatitis overlap syndromes and liver pathology. Gastroenterol Clin North Am 2017; 46: 345-364.
Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000 Jul; 75: 688-694.
Ludwig J, Batts KP. Practical liver biopsy interpretation: Diagnostic algorithms, 2nd edn. ASCP Press, 1998.
Levine A, Koletzko S, Turner D et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58: 795-806.
Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814.
Imam MH, Sinakos E, Gossard AA et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34: 1185-1192.
Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: Ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34: 901-910.
Sogo T, Fujisawa T, Inui A et al. Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis. Hepatol Res 2006; 34: 187-192.
Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int 2008; 28: 983-989.
de Ledinghen V, Le Bail B, Rebouissoux L et al. Liver stiffness measurement in children using FibroScan: Feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007; 45: 443-450.
Lindstrom L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013; 11: 841-846.
Rupp C, Rossler A, Halibasic E et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther 2014; 40: 1292-1301.
Ponsioen CY, Chapman RW, Chazouilleres O et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology 2016; 63: 1357-1367.
Floreani A, Rizzotto ER, Ferrara F et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100: 1516-1522.
Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: An evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008; 28: 209-220.
Tanaka A, Takikawa H. Geoepidemiology of primary sclerosing cholangitis: A critical review. J Autoimmun 2013; 46: 35-40.
Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002; 50: 713-717.
Miyagawa-Hayashino A, Egawa H, Yoshizawa A et al. Frequent overlap of active hepatitis in recurrent primary sclerosing cholangitis after living-donor liver transplantation relates to its rapidly progressive course. Hum Pathol 2011; 42: 1329-1336.
Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - A comprehensive review. J Hepatol 2017; 67: 1298-1323.
Sabino J, Vieira-Silva S, Machiels K et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016; 65: 1681-1689.
Iwasawa K, Suda W, Tsunoda T et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. Gut 2017; 66: 1344-1346.
Boberg KM, Chapman RW, Hirschfield GM et al. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385.
Gatselis NK, Zachou K, Papamichalis P et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score? Dig Liver Dis 2010; 42: 807-812.
Hiejima E, Komatsu H, Sogo T, Inui A, Fujisawa T. Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children. J Pediatr Gastroenterol Nutr 2011; 52: 470-473.
Mieli-Vergani G, Vergani D, Baumann U et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2018; 66: 345-360.
Sogo T, Takahashi A, Inui A, Fujisawa T, Ohira H, Takikawa H. Clinical features of pediatric autoimmune hepatitis in Japan: A nationwide survey. Hepatol Res 2018; 48: 286-294.